Severity
Low
FDA Drug recall · Reported August 12, 2015
Failed Dissolution Specifications
GlaxoSmithkline Consmer Healthcare recalled Panadol (acetaminophen) Extra Strength, 500 mg, a) 30 count (UPC 1-03-53100-91070-8, NDC … - a low-severity action.
Panadol (acetaminophen) Extra Strength, 500 mg, a) 30 count (UPC 1-03-53100-91070-8, NDC … was recalled by GlaxoSmithkline Consmer Healthcare in August 12, 2015. Reason: Failed Dissolution Specifications. Check the official notice for the remedy. Verify recall #D-1287-2015 with the FDA Drug before acting.
The recall
GlaxoSmithkline Consmer Healthcare issued this low-severity FDA Drug recall-Failed Dissolution Specifications.
Sourced from official FDA Drug enforcement records. Verify recall #D-1287-2015 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-1287-2015) was formally reported on August 12, 2015, with the manufacturer initiating the action on June 30, 2015. It is classified under Low severity (Class III), with a current status of Terminated. GlaxoSmithkline Consmer Healthcare is listed as the recalling firm, operating out of Moon Township, PA. Federal records list the affected scope as 17,675 cases.
The documented reason for this recall is: Failed Dissolution Specifications Distribution data in the federal record shows the product reached: Puerto Rico and Virgin Islands. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified low severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Low
Affected scope
17,675 cases
Related Recalls
6
5 from same agency
Panadol (acetaminophen) Extra Strength, 500 mg, a) 30 count (UPC 1-03-53100-91070-8, NDC 0135-0135-02), b) 60 count (UPC 1-03-53100-91080-7, NDC 0135-0135-03) and c) 100 count (UPC 1-03-53100-91090-6, NDC 0135-0135-04) bottles, Distributed by: GlaxoSmithKline Consumer Healthcare L.P, Moon Township, PA 15108
Failed Dissolution Specifications
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Low (Class III) |
| Status | Terminated |
| Recall number | D-1287-2015 |
| Date reported | August 12, 2015 |
| Date initiated | June 30, 2015 |
| Recalling firm | GlaxoSmithkline Consmer Healthcare |
| Firm location | Moon Township, PA |
| Affected scope | 17,675 cases |
| Distribution | Puerto Rico and Virgin Islands |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported August 12, 2015. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.